Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 15;8(9):15173-81.
eCollection 2015.

Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma

Chongyang Wu  1 , Xiangyang Wu  2 , Xiaoni Zhang  3 , Ye Chai  1 , Qi Guo  4 , Lijuan Li  1 , Lingling Yue  1 , Jun Bai  5 , Zhiping Wang  6 , Liansheng Zhang  1
Affiliations

Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma

Chongyang Wu et al. Int J Clin Exp Med. .

Abstract

Objective: The revised International Prognostic Index (R-IPI) aids in predicting the prognosis of patients with diffuse large B cell lymphoma (DLBCL), but R-IPI yields no significant differences in assessing different subtypes of DLBCL. It is necessary to identify patients with a high-risk of DLBCL and alternative therapy should be delivered as early as possible.

Methods: In total, 144 patients newly diagnosed with DLBCL including 63 GCB-DLBCL and 81 non-GCB-DLBCL and 30 healthy controls were enrolled. Peripheral monocytic myeloid-derived suppressor cells (M-MDSC) (CD14(+)HLA(-)DR(low/-)) were detected by flow cytometry and the percentage of monocytes (MΦ) was evaluated by completed blood count (CBC). The correlation between M-MDSC% and MΦ% was statistically analyzed.

Results: Compared with healthy controls, significant increase was observed in M-MDSC% and MΦ% in DLBCL patients (both P<0.001). Significant difference of M-MDSC% was found between GCB-DLBCL and non-GCB-DLBCL patients in both poor (P<0.001) and very good groups (P=0.03), whereas no statistical significance in the good group (P>0.05). The MΦ% in non-GCB-DLBCL patients was significantly higher than that in GCB-DLBCL counterparts merely in the poor group (P<0.001). Positive correlation was noted between MΦ% and M-MDSC in all DLBCL patients rather than in healthy controls (r=0.227 P=0.229).

Conclusion: The percentage of peripheral MΦ was positively correlated with M-MDSC% in patients with different subtypes and risks of DLBCL. Peripheral MΦ% and M-MDSC% combined with R-IPI score may be useful for predicting the prognosis of patients newly-diagnosed with DLBCL.

Keywords: Monocytic myeloid-derived suppressor cell; diffuse large B-cell lymphoma; monocyte; revised international prognostic index.

PubMed Disclaimer

Figures

Figure 1
Figure 1
M-MDSC% in subtype DLBCL patients and healthy controls. *Denotes statistical significance between GCB-DLBCL patients and healthy controls (P<0.001); **represents statistical significance between non-GCB-DLBCL patients and healthy controls (P<0.001).
Figure 2
Figure 2
MΦ% in subtype DLBCL patients and healthy controls. *DENOTES statistical significance between GCB-DLBCL patients and healthy controls (P=0.013); △represents statistical significance between non-GCB-DLBCL patients and healthy controls (P<0.001).
Figure 3
Figure 3
Correlation analysis between M-MDSC% and MΦ% in different risks of GCB-DLBCL patients.
Figure 4
Figure 4
Correlation analysis between M-MDSC% and MΦ% in different risk of non-GCB-DLBCL patients.
Figure 5
Figure 5
Correlation analysis between M-MDSC% and MΦ% in healthy controls.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Habermann T. New developments in the management of diffuse large B-cell lymphoma. Hematology. 2012;17(Suppl 1):S93–7. - PubMed
    1. Swerdlow SH, Campo E, Jaffe ES. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2010. p. 233.
    1. Goldman LS, Andrew I. Goldman’s Cecil Medicine. 24th edition. 2012. p. 1222.
    1. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2011;118:4173–4183. - PubMed
    1. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 2005;23:4117–4126. - PubMed

LinkOut - more resources